Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic expos... Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The lead product candidate of the company is AT-001, which is a novel ARI with broad systemic exposure and peripheral nerve permeability, developed for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart. 더 보기
- Company completed Late-Cycle review meeting with FDA - FDA no longer intends to hold Advisory Committee meeting - FDA Review of NDA continues to proceed as planned with PDUFA target action...
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against...
NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.63 | -7.42924528302 | 8.48 | 8.9 | 7.66 | 2315526 | 8.33040208 | CS |
4 | 2.05 | 35.3448275862 | 5.8 | 8.9 | 4.55 | 5143909 | 7.67506872 | CS |
12 | 2.36 | 42.9872495446 | 5.49 | 8.9 | 4.55 | 2460008 | 7.14577789 | CS |
26 | 1.63 | 26.2057877814 | 6.22 | 8.9 | 3.95 | 1679949 | 6.36873254 | CS |
52 | 5.46 | 228.451882845 | 2.39 | 9.39 | 1.79 | 1639641 | 5.27111464 | CS |
156 | -9.62 | -55.0658271322 | 17.47 | 19.14 | 0.4995 | 792544 | 4.28275387 | CS |
260 | -2.58 | -24.736337488 | 10.43 | 57.39 | 0.4995 | 532492 | 7.11976261 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관